President Donald Trump signed an executive order on December 18, 2025 that expedites the reclassification of marijuana, meaning it would be considered a less dangerous drug. Reclassification would make it easier to conduct research on medical marijuana and for Medicare and Medicaid recipients to access cannabidiol (CBD) products. It could also spur investment in an industry that’s seen its share of ups and downs. Must Read This comes at a time when cannabis use among boomers is, well, booming. The num ...

周四美国总统特朗普将大麻从最严格的管制药物类别中降级，放宽限制但并未完全合法化。 根据该行政令，大麻将从毒品的一类管制药物降至三类，与氯胺酮同级。但美国高级政府官员表示，此举不会改变执法部门对大 麻相关逮捕的处理方式。特朗普表示： 大麻命令并非法律，此命令在任何形式上都不会将大麻合法化。 同时，该命令还授权启动一项试点计划，允许美国联邦医保为癌症等患者的CBD（大麻二酚，一种非精神活性大麻化合物）产品 提供报销。这一医保计划预计将于明年启动。 特朗普的决定在共和党内部引发分歧。18名共和党参议员和26名众议院共和党议员近期致信总统反对重新分类，保守派非营利组 织CatholicVote也对此表示反对。 大麻股走势普遍下挫，ETF CNBS跌近16%、MSOS跌15.77%、MJ跌超10%，VFF的涨幅则收窄至3.71%。尽管遭到抛售，但相 关股票在行政令签署前仍录得大幅上涨，分析认为这或是投资者"买预期，卖事实"，了结获利资金离场。 虽然大麻重新分类将占据头条，但他革命性的医保试点项目将为数百万患有慢性疼痛和衰弱性疾病的老年人带来即时 的、改变生活的缓解和大麻素疗法的获取途径。 政策调整承认大麻医疗价值 此次 ...

美股频道更多独家策划、专家专栏，免费查阅>> 责任编辑：山上 工业大麻股盘前再度上涨，CbdMD涨近14%，Canopy Growth涨超7%，Tilray Brands涨近2%。 消息人士称，美国总统特朗普预计最早将于本周签署行政命令，放宽对大麻的分类管制，并首次在联邦 层面承认大麻的医疗用途。据悉，行政命令预计将指示美国缉毒局或司法部就重新分类管制颁布最终规 定，将大麻由一级管制物质降至第三级。同时，行政命令可能还包括指示国会通过法案，让合法的大麻 企业能够获得主要银行及金融机构的服务。消息人士称，行政命令亦有可能指示医疗保险及医疗补助服 务中心，允许在医疗保险报销大麻二酚(CBD)产品。 ...

Shares of U.S. and Canadian cannabis stocks continued their rally on Tuesday, after President Donald Trump a day earlier said he was "very strongly†weighing an executive order to reschedule the drug, a move that could lift some regulations on the substance. ...

【环球网报道 记者 李梓瑜】据美国《国会山报》报道，美国总统特朗普当地时间15日在白宫椭圆形办公室称，美国政府正"考虑"对大麻进行重新分 类，将其列为"危害性较低的毒品"。 此前，《华盛顿邮报》等媒体11日援引知情人士消息称，美国政府预计将推动联邦层面大幅放宽对大麻的管制，将对大麻及其衍生物的监管力度降至 与部分常见处方止痛药及其他药物相同的水平。特朗普10日在椭圆形办公室与美国共和党籍众议院议长迈克·约翰逊通话时讨论了这一计划，并预计通 过即将签署的行政令，要求联邦机构重新对大麻进行分类，从而放宽其获取限制。知情人士透露，约翰逊对此持怀疑态度，他列举多项研究及数据反 对重新对大麻进行分类。报道说，"此举不会使大麻合法化或去刑事犯罪化，但将降低相关研究门槛，并提高企业合法经营底线"。 据了解，大麻具有成瘾性，是联合国禁毒公约中被管制的麻醉药品。研究显示，使用大麻会影响人身心健康，长期大剂量使用可引起退行性变化的脑 疾病、严重的行为损伤、免疫系统抑制和神经疾病等。 然而，随着医用大麻以及非医用大麻在美国多州多地陆续放开，在联邦层面推进大麻合法化或去刑事犯罪化的运动悄然兴起。近来，美国大麻合法化 成蔓延之势，与利 ...

Core Insights - Tilray's stock, along with shares of other cannabis companies, experienced a significant increase following reports suggesting that President Trump may consider reclassifying marijuana as a less dangerous drug [1] Group 1: Market Reaction - The stock prices of Tilray and other cannabis firms soared, indicating a positive market sentiment driven by potential regulatory changes [1] - Investors are optimistic about the implications of reclassification on the cannabis industry, which could lead to increased market opportunities [1] Group 2: Regulatory Environment - The potential move by President Trump to reclassify marijuana could signify a shift in the regulatory landscape for cannabis, impacting both current and future investments in the sector [1] - Reclassification may reduce legal barriers and enhance the legitimacy of cannabis products, fostering growth within the industry [1]

US-listed cannabis stocks saw sharp premarket gains on Friday after fresh reporting pointed to a possible change in federal marijuana policy under President Donald Trump. The development revived inves... ...

Cannabis investors recently saw a jolt of optimism after President Donald Trump signaled support for covering CBD oil under Medicare. With the news, stock prices soared. A few of the companies that saw their stock prices soar up to 36% after the news include Green Thumb Industries, Curaleaf Holdings, Innovative Industrial Properties, Tilray Brands and Canopy Growth. (1) All of this growth came after The Commonwealth Project released a video touting the benefits of CBD oil for seniors. Subsequently, Trump ...

Core Viewpoint - The potential reclassification of cannabis from a Schedule I to a Schedule III drug by Trump could significantly impact the approximately $80 billion cannabis market, described as a "game changer" [2][7]. Group 1: Regulatory Changes - Trump is considering reclassifying cannabis, which is currently classified as a Schedule I drug under federal law, similar to cocaine [6]. - The reclassification would allow cannabis companies to benefit from different tax regulations and could stimulate investment interest [2][7]. - The discussion has primarily focused on moving cannabis to Schedule III, which includes substances like steroids and Tylenol with codeine [7]. Group 2: Market Reaction - Cannabis-related stocks experienced significant gains following Trump's announcement, with Canopy Growth rising over 26% and Tilray Brands soaring more than 41% [2][3]. - Cronos Group also saw a jump of over 14%, reaching a 52-week high [2]. - Many cannabis stocks are currently priced below $1 per share, meaning small price changes can lead to substantial percentage increases [5]. Group 3: Industry Sentiment - The public discussion by Trump has generated optimism within the industry, with Tilray's CEO expressing that the reclassification process may take about a year [7]. - Tim Seymour noted that bipartisan support appears to exist for changing the cannabis classification, suggesting that now may be an opportune time for investment in the sector [8].

Financial Data and Key Metrics Changes - In Q1 2025, the company achieved a net profit with an 87% improvement in gross margin compared to Q1 2024 [6] - Adjusted EBITDA in Q1 2025 resulted in a profit of $600,000, an improvement of almost $3,000,000 from an adjusted EBITDA loss of $2,200,000 in Q1 2024 [10] - Revenues for Q1 2025 were $12,500,000, a 4% increase from $12,100,000 in Q1 2024 [10] - Gross profit for Q1 2025 was $3,400,000, a 94% increase from $1,800,000 in Q1 2024 [12] - Net profit for Q1 2025 was approximately $200,000, compared to a loss of $6,000,000 in Q1 2024, marking a $6,200,000 improvement [13] Business Line Data and Key Metrics Changes - The German business grew 569% compared to Q1 2024, significantly offsetting a 66% decline in Israeli revenue [7][10] - Germany's share of total revenue in Q1 2025 increased to 62%, reflecting favorable market conditions and growing demand [11] Market Data and Key Metrics Changes - The company launched 12 new strains in Germany, contributing approximately €3,000,000 or 39% of cannabis flower sales in the region [6] - The decline in Israeli revenue was attributed to the cancellation of the Orenin deal, resulting in a revenue decrease of approximately $3,500,000 compared to Q1 2024 [11] Company Strategy and Development Direction - The company is focusing on execution and resource allocation to areas with the highest return on investment (ROI) [6] - Cost-cutting measures from shifting production facilities in Israel are positively impacting financial results, leading to increased gross margins [8] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the internal progress made strategically and operationally, which is now reflected in financial results [15] - The company aims to continue executing its strategy to maintain profitability [15] Other Important Information - Total assets as of March 31, 2025, were $44,934,000, an increase of 15% from $39,188,000 as of December 31, 2024 [13] - Total liabilities increased to $41,761,000, a 16% rise from $36,042,000 as of December 31, 2024 [14] Q&A Session Summary Question: Importance of the upcoming meeting regarding the 25% ownership of Focus - Management indicated that the approval is crucial for regulatory compliance and to facilitate the transition of long-term loans to equity, which is necessary for tax purposes [19][20]